<DOC>
	<DOC>NCT02404480</DOC>
	<brief_summary>This is a Phase 1, open-label, first-in-human, safety and pharmacokinetic study of PTC596 in patients with advanced cancer.</brief_summary>
	<brief_title>PTC596 in Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Patients must have histologically or cytologically confirmed solid malignancy that is metastatic or unresectable, for which standard curative measures do not exist, that has progressed on at least one line of standard therapy or for which no standard therapies exists Discontinuation of all other therapies (including other investigational drugs, radiotherapy, or chemotherapy) for the treatment of cancer ≥4 weeks (≥6 weeks if nitrosoureas, ≥12 weeks if radiotherapy) before initiation of study treatment Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Life expectancy of at least 3 months A measured or estimated creatinine clearance (CrCl) ≥60 mL/min/1.73 m2 Prior bone marrow/hematopoietic stem cell transplantation History of solid organ, bone marrow, or progenitor cell transplantation History of major surgical procedure within 28 days prior to start of study treatment Evidence of ongoing systemic bacterial, fungal, or viral infection. Known human immunodeficiency virus (HIV) infection or acquiredimmunodeficiency syndrome (AIDS)related illness Any of the following in the past 6 months: myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, congestive heart failure (New York Heart Association Class III or IV), cerebrovascular accident, transient ischemic attack, other arterial thromboembolic event, or pulmonary embolism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>